CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Adverse Event Profile of Blinatumomab in ALL

December 29th 2015

Using Blinatumomab in Acute Lymphoblastic Leukemia

December 29th 2015

Salvage Therapy in Acute Lymphoblastic Leukemia

December 29th 2015

MRD Monitoring in Acute Lymphoblastic Leukemia

December 29th 2015

Allogeneic Stem Cell Transplant in ALL

December 29th 2015

Minimal Residual Disease in ALL

December 29th 2015

Targeted and Chemotherapy Treatment Options in ALL

December 29th 2015

Induction and Post-Induction Therapy for Adult ALL

December 29th 2015

Acute Lymphoblastic Leukemia Patient Population

December 29th 2015

Overview on Management of Acute Lymphoblastic Leukemia

December 29th 2015

CAR T-Cell Therapy KTE-C19 Shows Promise in Non-Hodgkin Lymphoma

December 22nd 2015

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.

Dr. Brudno on Allogeneic T Cells Expressing an Anti-CD19 CAR in B-Cell Malignancies

December 7th 2015

Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.

High Response Rates Seen With CAR T-Cell Therapies for NHL

December 7th 2015

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Changing Treatment Landscape in Advanced Lung Cancer

October 1st 2015

Role of Gefitinib in EGRF-Mutant NSCLC

October 1st 2015

EGFR-Resistant Disease in Lung Cancer

October 1st 2015

Benefits of Liquid Biopsies in Lung Cancer

October 1st 2015

LUX-Lung 8: Afatinib Survival Benefit in Squamous NSCLC

October 1st 2015

Activity of Afatinib in Lung Cancer

October 1st 2015

Checkpoint Inhibition Squamous Cell and Nonsquamous Cell NSCLC

October 1st 2015